Skip to main content
logo
Coloplast A/S (CLPBY)
OTCMKTS · Delayed Price · Currency is USD
9.56
+0.15 (1.54%)
Oct 24, 2025, 3:59 PM EDT

Revenue by Product

Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202011 - 2019
Period Ending
Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 2011 - 2019
Ostomy Care
9.55B
Log In
Log In
Log In
Log In
Upgrade
Ostomy Care Growth
5.00%
Log In
Log In
Log In
Log In
Upgrade
Continence Care
8.54B
Log In
Log In
Log In
Log In
Upgrade
Continence Care Growth
7.34%
Log In
Log In
Log In
Log In
Upgrade
Interventional Urology
2.78B
Log In
Log In
Log In
Log In
Upgrade
Interventional Urology Growth
2.23%
Log In
Log In
Log In
Log In
Upgrade
Advanced Wound Dressings
3.03B
Log In
Log In
Log In
Log In
Upgrade
Advanced Wound Dressings Growth
-21.61%
Log In
Log In
Log In
Log In
Upgrade
Voice and Respiratory Care
2.11B
Log In
Log In
Log In
Log In
Upgrade
Voice and Respiratory Care Growth
8.98%
Log In
Log In
Log In
Log In
Upgrade
Biologics
1.03B
Log In
Log In
Log In
Log In
Upgrade
Biologics Growth
50.43%
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202011 - 2019
Period Ending
Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 2011 - 2019
Chronic Care Segment EBIT
10.44B
Log In
Log In
Log In
Log In
Upgrade
Chronic Care Segment EBIT Growth
5.94%
Log In
Log In
Log In
Log In
Upgrade
Interventional Urology Segment EBIT
976.00M
Log In
Log In
Log In
Log In
Upgrade
Interventional Urology Segment EBIT Growth
-0.10%
Log In
Log In
Log In
Log In
Upgrade
Advanced Wound Dressings Segment EBIT
1.15B
Log In
Log In
Log In
Log In
Upgrade
Advanced Wound Dressings Segment EBIT Growth
-0.35%
Log In
Log In
Log In
Log In
Upgrade
Other
-6.10B
Log In
Log In
Log In
Log In
Upgrade
Other Growth
6.54%
Log In
Log In
Log In
Log In
Upgrade
Voice and Respiratory Care Segment EBIT
736.00M
Log In
Log In
Log In
Log In
Upgrade
Voice and Respiratory Care Segment EBIT Growth
11.08%
Log In
Log In
Log In
Log In
Upgrade
Biologics Segment EBIT
101.00M
Log In
Log In
Log In
Log In
Upgrade
Biologics Segment EBIT Growth
58.14%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202011 - 2019
Period Ending
Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 2011 - 2019
European Markets
14.75B
Log In
Log In
Log In
Log In
Upgrade
European Markets Growth
4.86%
Log In
Log In
Log In
Log In
Upgrade
Other Developed Markets
7.75B
Log In
Log In
Log In
Log In
Upgrade
Other Developed Markets Growth
8.67%
Log In
Log In
Log In
Log In
Upgrade
Emerging Markets
4.53B
Log In
Log In
Log In
Log In
Upgrade
Emerging Markets Growth
4.96%
Log In
Log In
Log In
Log In
Upgrade

Other

Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202011 - 2019
Period Ending
Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 2011 - 2019
Ostomy Care Organic Growth
7.00%
Log In
Log In
Log In
Log In
Upgrade
Continence Care Organic Growth
8.00%
Log In
Log In
Log In
Log In
Upgrade
Advanced Wound Care Organic Growth
10.00%
Log In
Log In
Log In
Log In
Upgrade
Interventional Urology Organic Growth
5.00%
Log In
Log In
Log In
Log In
Upgrade
Total Organic Growth
8.00%
Log In
Log In
Log In
Log In
Upgrade
Voice and Respiratory Care Organic Growth
11.00%
Log In
Log In
Log In
Log In
Upgrade